Claims for Patent: 5,736,524

Summary for Patent: 5,736,524

Title:	Polynucleotide tuberculosis vaccine
Abstract:	Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
Inventor(s):	Content; Jean (Rhode-Saint-Genese, BE), Huygen; Kris (Brussels, BE), Liu; Margaret A. (Rosemont, PA), Montgomery; Donna (Chalfont, PA), Ulmer; Jeffrey (Chalfont, PA)
Assignee:	Merck & Co.,. Inc. (Rahway, NJ) N. V. Innogenetics S.A. (Ghent, BE)
Application Number:	08/338,992
Patent Claims:	1. A DNA vaccine comprising a plasmid vector comprising a nucleotide sequence encoding an antigen 85A mature protein operably linked to transcription regulatory elements, wherein upon administration into a mammal free from infection with Mycobacterium tuberculosis or Mycobacterium bovis said mammal is protected from infection by Mycobacterium tuberculosis or Mycobacterium bovis. 2. The DNA vaccine of claim 1 wherein the plasmid is V1Jns-85A[C2]. 3. The DNA vaccine of claim 1 wherein said vaccine is dicistronic, said vaccine further comprising an additional nucleotide sequence encoding an immunomodulatory or immunostimulatory gene, said additional nucleotide sequence being operably linked to regulatory elements. 4. The DNA vaccine of claim 3 wherein said additional nucleotide sequence is selected from the group consisting of nucleotide sequences encoding GM-CSF, IL-12, interferon, and a member of the B7 family of T-cell costimulatory proteins. 5. The DNA vaccine of claim 1 wherein said regulatory elements comprise the Cytomegalovirus promoter with the intron A sequence, and the Bovine Growth Hormone terminator. 6. The DNA vaccine of claim 1 wherein said mammal is a domestic mammal or livestock. 7. The DNA vaccine of claim 1 wherein said nucleotide sequence further encodes a signal sequence operably linked to said antigen 85A mature protein. 8. The DNA vaccine of 7 wherein the plasmid is V1Jns-85A[C3]. 9. The DNA vaccine of claim 7 wherein said signal sequence is a eukaryotic signal sequence from the gene encoding human tissue specific plasminogen activator. 10. The DNA vaccine of claim 9 wherein the plasmid is V1Jns-tPA-85A. 11. A method for immunization of a mammal against infection by Mycobacterium tuberculosis or Mycobacterium bovis comprising the administration of a DNA vaccine comprising a plasmid vector, said plasmid vector comprising a nucleotide sequence encoding an antigen 85A mature protein operably linked to transcription regulatory elements, wherein upon administration into a mammal free from infection with Mycobacterium tuberculosis or Mycobacterium bovis, said mammal is protected from infection by Mycobacterium tuberculosis or Mycobacterium bovis. 12. The method of claim 11 wherein said mammal is a domestic mammal or livestock. 13. The method of claim 11 wherein said DNA vaccine is dicistronic, said vaccine further comprising an additional nucleotide sequence encoding an immunomodulatory or immunostimulatory gene, said additional nucleotide sequence being operably linked to regulatory elements. 14. The method of claim 13 wherein said additional nucleotide sequence is selected from the group consisting of nucleotide sequences encoding GM-CSF, IL-12, interferon, and a member of the B7 family of T-cell costimulatory proteins. 15. The method of claim 11 wherein said regulatory elements comprise the Cytomegalovirus promoter with the intron A sequence, and the Bovine Growth Hormone terminator. 16. The method according to claim 11 wherein said nucleotide sequence further encodes a signal sequence operably linked to said antigen 85A mature protein. 17. The method of claim 16 wherein said signal sequence is a eukaryotic signal sequence from the gene encoding human tissue specific plasminogen activator.

Details for Patent 5,736,524

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26